Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Lineage Cell Therapeutics Inc’s current trading price is -55.56% away from its 52-week high, while its distance from the 52-week low is 39.99%. The stock’s price range over this period has fluctuated between $0.37 and $1.15. The company, operating within the financial sector, had a trading volume of approximately 0.8 million for the day, which was noticeably lower than the average daily share volume of 1.31 million over the last 3 months.
Lineage Cell Therapeutics Inc saw a rather unpredictable run in, in terms of market performance. The company’s stock reached its highest point at $1.15 on 07/23/24, while the lowest price for the same duration was marked at $0.37 on 04/09/25.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Lineage Cell Therapeutics Inc (LCTX) has experienced a quarterly decline of -26.30% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 116.71M and boasts a workforce of 77 employees.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.5347, with a change in price of -0.0269. Similarly, Lineage Cell Therapeutics Inc recorded 1,551,042 in trading volume during the last 100 days, posting a change of -5.00%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for LCTX stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.01.
LCTX Stock Stochastic Average
Today, Lineage Cell Therapeutics Inc’s raw stochastic average for the past 50 days stands at 74.95%, indicating a decline from the raw stochastic average of the last 20 days, which was 96.96%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 84.06% and 73.94% respectively.
LCTX Stock Price Performance Analysis
The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a gain of 1.71%.However, over the last six months, we can see a stronger performance of -40.87%. Over the last 30 days, the price of LCTX has fallen by 18.92%. And in the last five days, it has surged by 11.59%.
